A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome
Guillermo Garcia-Manero, Gary Gartenberg, David P. Steensma, Martin R. Schipperus, Dimitri A. Breems, Raquel de Paz, David Valcárcel, Britte Kranenburg, Manjula Reddy, Rami S. Komrokji
Research output: Contribution to journal › Article › Research › peer-review
Dive into the research topics of 'A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome'. Together they form a unique fingerprint.